Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $234,102.75 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,259 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75. Following the completion of the transaction, the insider now owns 184,947 shares of the company’s stock, valued at $5,964,540.75. This trade represents a 3.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Chi also recently made the following trade(s):

• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.00, for a total value of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.20, for a total value of $166,500.00.

Hims & Hers Health Stock Performance

HIMS stock traded down $0.09 during mid-day trading on Thursday, hitting $30.10. 8,470,645 shares of the company were exchanged, compared to its average volume of 9,937,356. The firm has a market cap of $6.58 billion, a P/E ratio of 69.91 and a beta of 1.25. Hims & Hers Health, Inc. has a 1-year low of $8.09 and a 1-year high of $35.02. The firm’s 50 day simple moving average is $24.28 and its 200 day simple moving average is $20.80.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.04) EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Cetera Advisors LLC acquired a new position in Hims & Hers Health during the 1st quarter worth approximately $396,000. SG Americas Securities LLC acquired a new position in Hims & Hers Health during the second quarter worth $2,223,000. Nisa Investment Advisors LLC grew its position in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Legacy Capital Group California Inc. acquired a new stake in Hims & Hers Health in the 2nd quarter valued at $1,699,000. Finally, Bank of New York Mellon Corp lifted its position in Hims & Hers Health by 67.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after buying an additional 273,473 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on HIMS shares. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price objective for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $21.43.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.